IBIO · iBio, Inc.

Ibio Inc Is A Clinical-Stage Biotechnology Company Using Artificial Intelligence (Ai) For The Development Of Hard-To-Drug Precision Antibodies For Obesity, Cardiometabolic, And Cardiopulmonary Diseases. Its Product Candidate Pipeline Includes Ibio-610, A Monoclonal Antibody Designed To Block Activin E; Ibio-800, A Bispecific Antibody Program Targeting Myostatin, Growth Differentiation Factor 11 (Gdf11), And Activin A; Ibio-600; Amylin Antibody; And Target 4, In Different Stages Of Development, Being Developed As Potential Therapies For Obesity And Cardiometabolic Disease. The Company Operates As One Reportable Segment, Which Is That Of A Biotechnology Company Leveraging Ai And Ml For The Development Of Hard-To-Drug Precision Antibodies.